Arrowhead Pharmaceuticals Director Sells 11,600 Shares for $1 Million
Perry's liquidity event comes as the Arrowhead stock price surged.
Overview
Michael S. Perry, a Director at Arrowhead Pharmaceuticals (NASDAQ:ARWR), sold 11,600 shares of common stock on Aug. 18, 2026, according to an SEC Form 4 filing.
Transaction value based on SEC Form 4 weighted average sale price ($87.30); post-transaction value based on Aug. 18, 2026, market close ($87.90).
Details
Arrowhead Pharmaceuticals, founded in 1989 and headquartered in Pasadena, California, represents a clinical-stage biopharmaceutical company with a market capitalization of $12.2 billion and 711 employees. The company's strategic focus on RNAi-based therapeutics provides a differentiated technological platform for addressing genetic and metabolic disorders with limited treatment options. With TTM revenue of $669.5 million and continued investment in its pipeline, Arrowhead demonstrates the capital-intensive nature of biopharmaceutical development. However, the company remains positioned to capture significant value upon successful advancement and commercialization of its clinical candidates.
Source
Originally published at www.fool.com.